Fulgent Genetics’ Q1 2026 report reveals a key inflection point as it balances expanding its laboratory testing services with advancing clinical trials for cancer therapeutics. Its proprietary AI-enabled diagnostics platform continues to support a broad and scalable test menu. However, revenue concentration from a major customer internalizing tests remains a critical risk. The company’s therapeutic segment is progressing through costly, early-phase clinical trials for FID-007 and FID-022, adding substantial R&D expense and cash burn. Cash flow improved sequentially but operating losses persist amid ongoing strategic investments.